HUTCHMED (NASDAQ:HCM) Shares Down 6% – Here’s Why

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) was down 6% during trading on Friday . The stock traded as low as $10.87 and last traded at $10.9150. Approximately 4,355 shares traded hands during trading, a decline of 90% from the average session volume of 41,652 shares. The stock had previously closed at $11.61.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. Bank of America decreased their price objective on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Weiss Ratings lowered shares of HUTCHMED from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $15.30.

HUTCHMED Trading Down 6.4%

The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. The stock has a 50-day simple moving average of $11.29 and a 200 day simple moving average of $13.42.

Institutional Investors Weigh In On HUTCHMED

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its stake in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the last quarter. UBS Group AG raised its position in HUTCHMED by 112.8% during the third quarter. UBS Group AG now owns 137,000 shares of the company’s stock worth $2,158,000 after acquiring an additional 72,614 shares during the last quarter. Amundi raised its position in HUTCHMED by 41.9% during the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after acquiring an additional 65,898 shares during the last quarter. M&G PLC lifted its holdings in shares of HUTCHMED by 26.7% in the fourth quarter. M&G PLC now owns 259,033 shares of the company’s stock valued at $3,367,000 after purchasing an additional 54,601 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of HUTCHMED by 157.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after purchasing an additional 34,248 shares in the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.